Psivida closer to Nasdaq listing

By Renate Krelle
Thursday, 20 January, 2005

Nanotechnology company Psivida (ASX:PSD) is to join a small band of Australian biotechs on the US Nasdaq market, announcing today it had filed a registration statement with the US Securities and Exchange Commission in relation to its planned listing of American Depositary Shares (ADSs).

Psivida expects its ADSs to begin trading before the end of January.

"The Nasdaq listing will enable a range of domestic US institutions whose investment guidelines are restricted to US securities, to trade our shares as a US ADR security," said CEO Gavin Rezos in an interview last year. "This ADR listing also provides potential representation of Psivida in US-based nanotechnology indices,"

Psivida currently trades on the ASX, on Frankfurt's XETRA and in the UK's OFEX International Market Service (IMS). Melbourne's Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) and Genetic Technologies (ASX:GTX, NASDAQ:GNTLY) are also listed on Nasdaq.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd